Patient-Reported Outcomes in the Soluble Guanylate Cyclase Stimulator in Heart Failure Patients with Preserved Ejection Fraction (SOCRATES-PRESERVED) Study

Vericiguat, in exploratory hypothesis-generating analyses, was associated with clinically important improvements in patients' health status, as assessed by the KCCQ and EQ-5D. Further studies should be conducted to test the hypothesis that vericiguat improves physical functioning and health-related quality of life in patients with HF with preserved ejection fraction.